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ABSTRACT 
The class B G protein-coupled receptor (GPCR) calcitonin receptor (CTR) is a drug target for 
osteoporosis and diabetes. N-glycosylation of asparagine 130 in its extracellular domain (ECD) enhances 
calcitonin hormone affinity with the proximal GlcNAc residue mediating this effect through an unknown 
mechanism. Here, we present two crystal structures of salmon calcitonin-bound, GlcNAc-bearing CTR 
ECD at 1.78 and 2.85 Å resolutions and analyze the mechanism of the glycan effect. The N130 GlcNAc 
does not contact the hormone. Surprisingly, the structures are nearly identical to a structure of hormone-
bound, N-glycan-free ECD, which suggested that the GlcNAc might affect CTR dynamics not observed 
in the static crystallographic snapshots. Hydrogen-deuterium exchange mass spectrometry and molecular 
dynamics simulations revealed that glycosylation stabilized a β-sheet adjacent to the N130 GlcNAc and 
the N-terminal α-helix near the peptide-binding site, while increasing flexibility of the peptide-binding 
site turret loop. These changes due to N-glycosylation increased the ligand on-rate and decreased its off 
rate. The glycan effect extended to RAMP-CTR amylin receptor complexes and was also conserved in the 
related CGRP receptor. These results reveal that N-glycosylation can modulate GPCR function by 
altering receptor dynamics.  
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INTRODUCTION 
The calcitonin receptor (CTR) is a class B G protein-coupled receptor (GPCR) and its activation 
regulates calcium homeostasis and bone turnover [1, 2]. CTR is a drug target for treating Paget’s disease, 
osteoporosis, and hypercalcemia, which all result from abnormal bone turnover and calcium regulation. A 
32-amino acid peptide hormone salmon calcitonin (sCT), which has higher affinity than human calcitonin, 
has been developed as a drug for these clinical applications [3]. CTR can form a heterodimeric complex 
with any of three accessory Receptor Activity-Modifying Proteins (RAMPs), which enhance affinity for a 
37-amino acid peptide hormone amylin [4-6]. Amylin is co-secreted with insulin from pancreatic β-cells 
and activates the CTR:RAMP complexes expressed in the brain [7, 8]. The amylin receptors are 
designated AMY1, AMY2, and AMY3 for CTR complexes with RAMP1, -2, and -3 respectively. Amylin 
improves blood glucose control by reducing appetite, slowing gastric emptying, and inhibiting glucagon 
secretion [9]. A chimera of rat and human amylin pramlintide has been developed to treat type I and type 
II diabetes [10]. Understanding the molecular mechanism of how peptide hormone binding affinity is 
determined at CTR will provide an important foundational basis to develop peptide drugs targeting both 
CTR and the amylin receptors.             
CTR has an extracellular domain (ECD) and a plasma membrane-embedded seven transmembrane 
domain (TMD). A general mechanism of peptide hormone interaction with class B GPCRs has been 
proposed; the receptor ECD first binds to the C-terminal half of the peptide hormone to increase the local 
concentration of the N-terminal half of the peptide, which subsequently binds and activates the receptor 
TMD [11]. Our previous report with alanine-scanning mutagenesis of sCT(22-32) and molecular 
modeling suggested a relatively unstructured ECD-bound sCT conformation with a β-turn near its C-
terminus [12]. This model was consistent with a crystal structure of CTR ECD bound with a sCT analog, 
which showed precisely how the hormone binds the ECD [13]. More recently, the cryo-EM structure of 
full length CTR in complex with sCT(1-32) and the heterotrimeric Gs protein revealed the molecular 
interaction of the N-terminal half of sCT with CTR TMD [14, 15]. sCT(8-19) formed an amphipathic 
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helix toward a hydrophobic TMD environment and several hydrogen bond interactions were observed 
between sCT N-terminal residues and CTR TMD. The receptor residues needed for association with hCT 
and rat amylin have been examined by mutagenesis in the presence and absence of RAMP1 [16]. 
Interestingly, this study examined the interface of RAMP1 ECD with CTR, and suggested that RAMP1 
might exert its functions, at least in part, by altering the dynamics of the CTR.   
CTR is a glycoprotein with four N-glycosylation sites, all of which are located in the ECD: N28, 
N73, N125, and N130. The first of these sites is absent in a functional splice variant [17]. We reported 
that CTR N-glycosylation enhanced calcitonin binding affinity ~10-fold for the isolated ECD [18]. The 
proximal GlcNAc residue of CTR N130 was largely responsible for the affinity enhancement along with a 
small contribution from the proximal GlcNAc at N125. In addition, Liang et al. showed that N-
glycosylation of CTR N130 enhanced both peptide binding affinity and signaling potency ~10-fold at 
full-length CTR [14]. To date, the molecular basis for this significant glycan effect on the function of this 
clinically important GPCR remains unknown. The sCT-CTR ECD crystal structure used N-glycan-free 
ECD expressed in E. coli. The full-length cryo-EM CTR structure included N-glycosylated ECD, 
however, the ECD was poorly resolved and not modeled due to apparent inter-domain flexibility even 
when bound by ligand. Thus, despite the recent structural insight into the molecular pharmacology of 
ligand binding to the CTR we still lack a structural understanding of the glycan effect. More broadly, the 
effects of N-glycosylation on GPCR structure and function in general remain poorly understood despite 
other notable examples of significant modulation of GPCR function by N-glycosylation [19].  
In the current study, we sought to understand how N-glycosylation modulates GPCR function using 
CTR as a model system. We obtained two crystal structures of sCT-bound human CTR ECD containing 
the proximal GlcNAc residues at the N-glycosylation sites and compared them to the prior N-glycan-free 
structure. Molecular dynamics (MD) simulations and hydrogen-deuterium exchange mass spectrometry 
(HDX-MS) were performed to gain a molecular insight into the receptor dynamics between the 
glycosylated and non-glycosylated forms of the ECD. Analysis of the low frequency oscillations between 
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the simulations highlighted key structural differences which are consistent with the effects of the GlcNAc 
residues on sCT binding kinetics and CTR ECD dynamics determined experimentally by HDX-MS. Our 
results indicate that while glycosylation at CTR N130 does not directly contact sCT and does not 
significantly alter the global conformation of the CTR ECD, it does modulate the ECD dynamics. In 
addition, we show that the glycan effect is maintained in the heterodimeric AMY1 and AMY2 receptors 
and is also conserved in at least one other class B GPCR. This study is the first, to our knowledge, to 
show that N-glycosylation can modulate GPCR function by controlling receptor dynamics.  
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RESULTS 
Crystal structures of sCT bound to proximal GlcNAc-bearing CTR ECD  
The human CTR ECD was fused with maltose-binding protein (MBP) at its N-terminus to facilitate 
crystallization [20] and a (His)6 tag at its C-terminus for purification. Two versions of the fusion protein 
were constructed with CTR residues 38-141 or 40-141. The fusion proteins were expressed as secreted 
proteins in HEK293 GnTI- cells [21] and the three glycosylation sites in the ECD, N73, N125, and N130 
were trimmed to single GlcNAc residues with Endo H for crystallization. Crystals of the 38-141 construct 
obtained with sCT(16-32) at neutral pH diffracted to 1.78 Å resolution and crystals of the 40-141 
construct obtained with sCT(22-32) at pH 4.7 diffracted to 2.85 Å resolution. Both structures were solved 
by molecular replacement and refined to good geometry and R factors (Table 1). The 1.78Å structure had 
two molecules in the asymmetric unit and the 2.85Å structure had a single molecule (Figure S1). The two 
complexes in the 1.78Å structure were similar except that the C72-C112 disulfide in the Mol B CTR ECD 
was partially broken, which required fitting alternative mainchain conformations for a segment near the 
disulfide. Despite this issue, the peptide-binding mode was the same in both complexes. 2mFo-DFc 
electron density maps showed clear density for the proximal GlcNAc residue of CTR ECD N130 in both 
structures (Figure S2). Electron density for the N125 GlcNAc residue in the 1.78Å structure was very 
poor so this glycan was omitted from the final model. Electron density of moderate quality was observed 
for the N73 GlcNAc in both structures. Hereafter we use Mol A of the 1.78Å structure for Figures.   
The two structures exhibited the same binding mode for the primary ECD-binding 22-32 portion of 
the peptide despite their crystallization at significantly different pH values (Figure 1A and 1B). The 
defining peptide feature was a type II β-turn near the C-terminus. The affinity-enhancing N130 GlcNAc 
residue adopted the same conformation in both structures and notably, there were no direct contacts 
between the GlcNAc and the sCT peptide. The N-terminal α1 helical region of CTR ECD adopted a 
different conformation in the 1.78Å and 2.85Å structures, which may be in part affected by fusion to 
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MBP (Figure 1A, 1B, and S1). Key molecular interactions of sCT with the glycosylated CTR ECD 
include hydrogen bonds between sCT T25 and CTR D101, the type II β-turn of sCT G28 to T31 
contacting the CTR turret loop, the C-terminal P32 interaction with CTR W79 “Trp Shelf”, and hydrogen 
bonds between the sCT P32 amide and the CTR S129 backbone (Figure 1C and 1D). A unique interaction 
not previously observed is CTR Y41 in the flexible α1 region forming a hydrogen bond with sCT T25 in 
the 1.78Å structure (Figure 1C). This interaction was not present in the 2.85Å structure (Figure 1D).   
Effects of mutating CTR ECD residues near the N130 proximal GlcNAc 
The structures suggested possible interaction of the N130 GlcNAc with neighboring CTR ECD 
residues; F119, W128, T132, M133, and T109 all have atoms within 4.5 Å of the GlcNAc. We 
investigated the mutational effects of these residues on peptide hormone affinity. In addition, we tested 
whether peptide affinity is still decreased by PNGase F-catalyzed receptor deglycosylation. If any of these 
residues mediates the GlcNAc effect, then mutation of the residue should decrease peptide affinity and 
peptide affinity should be unaffected or less-affected when N-glycans are removed by PNGase F 
treatment. We expressed and purified MBP-CTR ECD with the single F119H, F119L, W128H, M133A, 
or T109V mutation using HEK293T cells. T132 was not mutated, because this would eliminate N-
glycosylation of N130. A fluorescence polarization/anisotropy assay was used to examine binding affinity 
of the purified fusion proteins for a FITC-labeled high-affinity calcitonin analog AC413(6-25) Y25P 
probe as previously described [18]. F119H and F119L mutations of CTR ECD designed to eliminate 
contact with the GlcNAc acetyl moiety decreased the peptide affinity by 3-fold. However, PNGase F 
treatment of these mutant receptors showed a further ~10-fold decrease in peptide affinity (Figure S3B, 
S3C, S3F, and S3G). CTR ECD W128 locates in the sCT-binding pocket and is within the hydrogen bond 
distance of the main chain carbonyls of sCT T27 and G28 (Figure 1C and 1D). The W128H mutation 
designed to maintain this hydrogen bonding potential while removing the indole contact with the GlcNAc 
acetyl moiety dramatically diminished the peptide binding affinity. When the W128H mutant receptor 
was treated with PNGase F, the peptide affinity appeared to be further decreased, although the full 
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binding curve could not be obtained due to very weak affinity (Figure S3J and S3K). The M133A 
mutation of CTR ECD did not alter peptide affinity significantly (Figure S3N). CTR ECD T109 forms 
hydrogen bonds with two water molecules that connect T109 to N130 GlcNAc through hydrogen bonds 
(Figure S3O). The T109V mutation designed to eliminate the hydrogen bonds decreased the peptide 
affinity, but once again the peptide affinity was further decreased ~10-fold by PNGase F treatment 
(Figure S3P and S3Q). These results suggested that the side chains of these CTR residues do not mediate 
the GlcNAc effect. 
The GlcNAc-bearing structures differ little from the structure of sCT bound to N-glycan free CTR ECD  
We compared our structures to the structure of sCT bound to bacterially produced, N-glycan free 
CTR ECD [13] to look for GlcNAc effects on ECD and/or peptide conformations. Surprisingly, 
superimposition of our structures with the three sCT-CTR ECD complexes present in the asymmetric unit 
of PDB ID 5II0 (2.1 Å resolution) revealed very similar receptor and peptide conformations (Figure 2A 
and 2B). Mol A ECD of the 1.78 Å structure aligned to the three ECD molecules of 5II0 with RMSD 
values of 0.377 Å, 0.378 Å, and 0.349 Å, respectively. The 2.85 Å structure ECD aligned to the three 
ECD molecules of 5II0 with RMSD values of 0.358 Å, 0.298 Å, and 0.359 Å, respectively. The primary 
difference among the ECDs was the variability in the conformation of the N-terminal part of α1, 
indicating flexibility of this region that is most likely enabled by residue Gly 44. An interesting side note 
is that Y41 of CTR ECD Mol C in the glycan-free structure appears as though it might have formed a 
hydrogen bond with sCT T25 as observed in our 1.78 Å structure, if not for a urea molecule from the 
crystallization solution taking its place (Figure S4). The binding conformation of sCT for the CTR ECD 
was largely unchanged by N-glycosylation. sCT T25 to P32 residues were minimally affected, if at all, by 
CTR glycosylation. Y22 to R24 sCT residues positioned in several directions, which is likely due to 
increased flexibility of Y22 to R24 that escape the peptide-binding pocket of CTR ECD. These 
comparisons of static crystallographic snapshots failed to provide an obvious explanation for the glycan 
effect. 
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Receptor N-glycosylation increases the on rate and slows the off rate of sCT binding  
We reasoned that the N130 GlcNAc might alter receptor dynamics. Indeed, our previous study 
suggested that RAMP1 functions in part by altering CTR ECD dynamics [16]. To enable experiments 
testing this hypothesis we expressed and purified MBP-free CTR ECD to remove any complications from 
the presence of MBP. This was done by purifying MBP-TEV cleavage site-CTR ECD fusions and 
removing the MBP with TEV protease. Three versions of CTR ECD were purified: Endo H-treated CTR 
ECD WT and N130D mutant produced in HEK293S GnTI- cells, and glycan-free CTR ECD WT 
produced in E. coli. Endo H was used to trim the glycans to the proximal GlcNAc residues. The CTR 
ECDs were highly purified, although the Endo H-treated CTR ECD WT and N130D proteins did exhibit a 
second minor band on SDS-PAGE due to incomplete Endo H trimming (Figure S5). The glycan-free 
ECD exhibited a tendency to aggregate at high concentrations; Johansson et al. also noted this behavior 
[13], and they crystallized their protein in the presence of 2 M urea to overcome this problem. Fortunately, 
the N130D ECD exhibited better solubility characteristics than the E. coli-produced protein, but it still 
could not be concentrated as high as the glycosylated WT ECD.   
First, we measured the equilibrium binding affinities of sCT for the three CTR ECDs in the FP assay. 
The CTR ECD N130D mutation or the complete absence of N-glycans significantly decreased FITC-
labeled sCT affinity by over 5-fold (Figure 3A and Table 2). Competitive binding assays also showed the 
affinity decrease of non-labeled sCT(22-32) by the N130D mutation or with glycan-free CTR ECD 
(Figure 3B and Table 2). These results are consistent with our previous findings with MBP-CTR ECD 
fusion proteins. Next, we analyzed the kinetics of binding to dissect the N-glycosylation effect on the on 
and off rates. For these experiments we used biolayer interferometry to measure real-time binding of the 
purified ECDs to sCT immobilized on the sensor tips. Figure 3C-3E shows the binding profile generated 
from each of the three CTR ECD proteins. Both association and dissociation rates for CTR ECD were 
altered by receptor N-glycosylation; sCT association was 2.8-fold decreased, whereas sCT dissociation 
was over 2-fold increased by the N130D mutation (Figure 3C and 3D and Table 3). The complete absence 
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of N-glycans in E. coli-produced CTR ECD further decreased the sCT association rate (Figure 3D and 3E 
and Table 3). The calculated affinities (KD) from association and dissociation rates were comparable to 
the KD values obtained from the equilibrium FP assays.         
N-glycosylation of CTR N130 alters ECD conformational dynamics 
The N-glycosylation effect on the conformational dynamics of CTR ECD was analyzed using a 
combination of hydrogen-deuterium exchange mass spectrometry (HDX-MS) (Figure 4) and molecular 
dynamics simulations (Figure 5). HDX-MS probes the exchange rate between amide hydrogens within a 
protein and deuterium in the solvent, which is affected by solvent exposure and conformational dynamics 
and/or flexibility of the protein; higher deuterium uptake represents more solvent-exposure and/or higher 
conformational dynamics of the protein. For these experiments we compared the Endo H-treated WT and 
N130D CTR ECD proteins. The N-terminal part of the CTR ECD WT α1 helical region (residues 41-52) 
showed significantly less HDX signal than the N130D mutant (Figure 4A). The HDX signal of residues 
41-52 reached a plateau over time. We found that the β3 strand and its adjacent loops (residues 84-96) 
showed a decrease in HDX signal with N-glycans (Figure 4B). The peptide fragment of residues 81-90 
showed minimal changes by N-glycans (Figure S7) suggesting that the HDX signal of residues 84-96 
resulted from residues 91-96. The β4 strand and its distal residues (residues 107-118) of CTR ECD WT 
also showed a significant decrease in HDX signal compared to the N130D mutant (Figure 4C). 
Interestingly, the conformational dynamics of the turret loop residues 119-127 in CTR ECD WT was 
greater than that of the N130D mutant (Figure 4D). We also obtained HDX-MS results of CTR ECDs in 
the presence of an excess of sCT (22-32). The differences in HDX signal between sCT-bound CTR ECD 
WT and N130D were consistent with those with ligand-free CTR ECD WT and N130D (Figure S6).  
We used molecular dynamics (MD) simulations coupled with principle component analysis (PCA) to 
investigate if CTR ECD dynamics are altered by receptor N-glycosylation. The first seven, non-zero, 
eigenvectors which covered 87-91% of the total motion were analyzed for each structure. Our high 
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resolution 1.78Å CTR ECD structure and glycan-free structure (PDB 5II0) were used for the simulations. 
In the glycan-free CTR ECD crystal structure, three molecules of CTR ECD were in the asymmetric unit 
and the conformation of amino-terminal residues 34-43 was different among three molecules (Figure 2 
and S4). The residue 136 of the 1.78 Å CTR ECD structure was modeled as the C-terminal end of the 
CTR ECD since electron density beyond this residue was very weak to model. For exact residue 
comparison, MD simulations were performed with residues 44 to 136 of the GlcNAc-bearing and glycan-
free CTR ECD. PCA highlighted that the N-terminal α1 helical domain showed a significant reduction in 
the RMSF (Root Mean Squared Fluctuation) in the structures containing the GlcNAc residues compared 
to the non-glycosylated form. The reduced motion in domain can be attributed directly to the presence of 
the glycosylation (Figure 5A and 5C). The simulation result was consistent with the decreased flexibility 
inferred by HDX-MS in which CTR ECD residues 41 to 52, 84 to 96, and 107 to 118 were stabilized by 
the GlcNAc residues (Figure 5A, 5C, 5D, and 5E). In the simulations, N-glycosylation also stabilized 
residues 61-63 at the beginning of the loop following α1 (Figure 5A and 5D).  Residues at the apex of the 
turret loop showed slightly increased flexibility with GlcNAcs compared to the loop of glycan-free CTR 
ECD, although this effect was subtle when visually represented (Figure 5F). We also performed MD 
simulations with the 1.78 Å CTR ECD structure model after the GlcNAc residues of N73 and N130 were 
deleted. The CTR ECD with GlcNAcs removed produced virtually the same RMSF as that of glycan-free 
CTR ECD (PDB 5II0) (Figure 5B). The RMSF patterns from MD simulations were consistent with the 
HDX-MS results and together they strongly suggest that the N130 proximal GlcNAc residue stabilizes the 
adjacent β-sheet and the N-terminal α-helix while increasing turret loop flexibility. 
Receptor N-glycosylation also enhances peptide hormone affinity for amylin and CGRP receptors 
Since glycosylation affected CTR ECD conformational dynamics we asked if the glycan effect was 
altered by binding of the RAMP1 or RAMP2 accessory proteins to CTR in the context of the AMY1 and 
AMY2 receptor ECD complexes. First, we expressed and purified a tethered fusion protein of the RAMP1 
and CTR ECDs secreted from HEK293S GnTI- cells and compared its peptide binding selectivity profile 
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to that of the isolated CTR ECD in the FP assay. The RAMP1-CTR ECD fusion showed a marked 
increase in affinity for the amylin analog AC413 when compared to CTR ECD alone, whereas sCT bound 
both proteins with similar affinities (Figure S8A and S8B). The tethered RAMP1-CTR ECD fusion thus 
exhibited the peptide binding profile expected of the AMY1 receptor. Next, we examined the effects of N-
glycosylation on hormone binding to the RAMP1-CTR ECD fusion. RAMP1, which lacks N-
glycosylation sites, is predicted to bind to the N-terminal α-helix of CTR and make minimal contact with 
the peptide (Figure S8C). PNGase F treatment of the RAMP1-CTR ECD fusion dramatically decreased 
the affinity of AC413 (Figure S8D and S8E and Table 2). The N130D mutation in CTR of the RAMP1-
CTR ECD fusion also significantly decreased the peptide affinity, although not to the same extent as 
PNGase F treatment probably due to a small contribution from the N125 glycan as we previously 
observed for CTR ECD (Figure S8D and Table 2) [18]. We also purified a RAMP2-CTR ECD fusion.  In 
this case RAMP2 ECD adds one additional N-glycosylation site. The RAMP2-CTR ECD fusion showed a 
higher amylin analog AC413 affinity, compared to CTR ECD alone (Figure S9A and S9B). Consistent 
with the results of RAMP1-CTR ECD fusion, PNGase F treatment of RAMP2-CTR ECD fusion 
significantly decreased the AC413 affinity (Figure S9C and S9D).  
Last, we asked if the glycan effect is conserved in any other class B GPCRs. Amino acid sequence 
alignment of the ECDs of the fifteen human class B GPCRs revealed that the CTR N130 glycosylation 
site is conserved in six of the receptors including the related CTR-like receptor (CLR), the two 
parathyroid hormone receptors and the two corticotropin releasing factor receptors (Figure S10A). CLR is 
an obligate heterodimer with RAMPs and the CLR:RAMP1 complex is the calcitonin-gene related 
peptide (CGRP) receptor, which binds both CGRP and adrenomedullin (AM) peptides. We built a 
RAMP1:CLR ECD model bearing proximal GlcNAc residues by adding the glycans to the recently 
reported cryo-EM structure of the CGRP receptor (PDB 6E3Y) [22] (Figure S10B). Although the cryo-
EM density for the ECD complex was low resolution, density for the proximal GlcNAc was apparent at 
each of the three glycan sites. This modeling exercise was consistent with the CLR N123 proximal 
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GlcNAc (equivalent to CTR N130) adopting the same conformation observed in our CTR ECD structures 
and being too distant to contact the bound peptide. We purified a tethered RAMP1-CLR ECD fusion 
protein secreted from HEK293T cells and evaluated the effect of receptor N-glycosylation on binding of a 
high-affinity AM analog in the FP assay. PNGase F treatment significantly reduced the peptide affinity 
and the CLR N123 site was largely responsible for this effect as indicated by reduced affinity of the 
RAMP1-CLR fusion containing the CLR N123D mutation (Figure S10C and S10D and Table 2). These 
results indicated that the affinity-enhancing effect of receptor N-glycosylation is conserved in at least one 
other class B GPCR.         
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DISCUSSION 
Structures of sCT bound to the glycosylated CTR ECD 
 The two new crystal structures of glycosylated CTR ECD with bound sCT C-terminal fragments 
reported here revealed receptor and peptide conformations in good agreement with those previously 
reported for the sCT-bound glycan-free ECD [13]. N-glycosylation clearly does not cause major 
conformational changes in the receptor or the bound peptide.. Apart from the issue of how N-glycans 
affect ligand-receptor interaction our structures revealed new information potentially relevant to the N-
terminus of CTR and its ability to contact the ligand. In our high-resolution structure we observed a 
unique interaction of CTR Y41 with T25 of the peptide hormone that was not previously observed.  This 
could be an artifact resulting from fusion of the ECD with MBP, but it nonetheless demonstrates the 
potential for N-terminal CTR residues to contact the ligand. Considerable flexibility of this CTR region is 
evident in comparisons of all the structures now available (Figure 2). Interestingly, previous cross-linking 
data with full-length CT and CTR identified proximity between residue 26 of CT and residue 30 of CTR 
[23]. It thus appears that the N-terminal region of CTR, including several residues lacking in our 
crystallization constructs, is probably quite dynamic and thereby able to approach the ligand. Whether 
such contacts play a significant role in CT signaling in cells is unclear. Notably, structural studies of the 
related CGRP and adrenomedullin receptors did not show the same level of flexibility in the N-terminal 
α-helix of CLR [24-26]. The CTR ECD appears to be more dynamic than that of CLR, at least for this 
region, and this might contribute to differences in the pharmacology of these two related receptors. 
Mechanism of N-glycan-mediated enhancement of CTR peptide hormone affinity 
N-glycosylation has been reported to play multiple functions, such as in protein folding, stability, 
and receptor-ligand interactions, all of which can contribute to ligand binding affinity [28-30]. N-
glycosylation effects on sCT-CTR interaction had been elusive with mixed results [31-33] until recent 
reports clearly demonstrated a significant enhancement of hormone affinity conferred by N-glycosylation 
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of CTR N130 [14, 18]. Nonetheless, the molecular mechanism of the glycan effect remained unknown. 
The crystal structures with GlcNAc-bearing CTR presented here showed that the proximal GlcNAc 
residue of N130 does not make direct contact with the sCT peptide. When we compared these structures 
to that of the glycan-free CTR ECD, the structural differences were minimal. This suggested that the 
static crystal structures were missing important differences in dynamics. We used MD simulations and 
HDX-MS in combination to probe the conformational dynamics of the glycosylated vs. the non-
glycosylated forms of the protein. While MD and HDX-MS do report on the conformation dynamics, it 
should be noted that HDX will only report on mobility where there are changes in solvent accessibility of 
the peptide backbone; thus it would not be expected that there would be perfect agreement between MD 
simulations and HDX experiments [34]. In addition, our HDX-MS experiments compared WT 
glycosylated ECD to the N130D mutant that retains glycosylation at the N73 and N125 sites, whereas the 
MD simulations compared WT ECD with GlcNAcs to glycan-free WT ECD. Unfortunately, solubility 
challenges with the MBP- and glycan-free WT ECD prevented us from obtaining good HDX-MS data on 
this sample. 
Despite the imperfect comparison, the HDX-MS results and the MD simulations were largely in 
agreement and together they indicated that the CTR N130 N-glycan altered CTR ECD conformational 
dynamics. These effects on dynamics enhanced the ligand on rate and slowed its off rate. Several regions 
of the ECD were stabilized by glycosylation including the N-terminal region of the CTR α-helix, which is 
distant from the N-glycan sites, the β-sheet comprising the β3 and β4 strands adjacent to the N130 
GlcNAc responsible for ligand affinity enhancement, and residues 61-63 near the N73 GlcNAc. The 
stabilization of residues 41-52 may indirectly enhance the residency time of the bound peptide by acting 
as a buttress to position the β1-β2 loop of the receptor against the ligand. The side chain of Met 48 of 
CTR ECD is within ~4 Å distance from the W79 Trp shelf in our crystal structures. The stabilized 
dynamics of Met 48 could help Trp 79 confine its position and interact with C-terminal Pro 32 of the 
calcitonin peptide (Figure 1C). The β-sheet is a crucial structural element of the ECD fold, so its 
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stabilization would be expected to contribute to overall domain stability including the peptide-binding site. 
The changes in residues 61-63 probably result from effects of the N73 GlcNAc on the adjacent Arg 74, 
which forms polar interactions with residues 62 and 63. This is likely of little importance because the N73 
glycan has no effect on peptide hormone affinity [18]. In contrast to the multiple areas of decreased 
flexibility resulting from glycosylation, flexibility of the turret loop adjacent to the N130 glycan site was 
increased, although this effect was more evident in the HDX-MS data than in the MD simulations. The 
basis for this small discrepancy is unclear, but whatever the reason any alteration in turret loop dynamics 
is likely very relevant to ligand residency because the peptide β-turn directly contacts this loop.  
How does the N130 GlcNAc exert its effects on CTR dynamics? Despite the apparent interaction of 
the GlcNAc with neighboring CTR residues such as F119 and W128, we were unable to find evidence 
that these residues mediated the GlcNAc effect. Although mutation of some of the residues in the vicinity 
of the GlcNAc resulted in decreased peptide affinity, in all cases examined the affinity of the mutant 
receptor was still further decreased by enzymatic deglycosylation. These results suggested that the 
GlcNAc effect is either mediated through a combination of these residues such that mutating any one 
alone does not reveal a significant effect or that the effect is mediated directly through the N130 residue 
itself or perhaps T132, which we could not mutate. Previous studies with glycopeptides have shown that 
N-glycans can alter conformational preference of the peptide backbone near the glycosylation site [35, 
36]. The CTR N130 GlcNAc effect could be mediated through effects on the N130 backbone. 
Interestingly, the N130 backbone amide and carbonyl make hydrogen bonds with the backbone of T109 
in the β4 strand, thus providing a physical link between the N130 glycan site and the adjacent β-sheet that 
is stabilized by the glycan. Additionally, glycosylation has recently been shown in MD simulations to 
control fluid dynamics of the bulk solvent and as a knock on effect of this altering allosteric 
communication to non-juxtaposed regions of the receptor [37]. In these cases, the underlying mechanism 
seems to be at least in part due to dynamic allostery, where changes in the dynamics (rather than the static 
structure) of a protein at one site cause effects at a more distant location [38, 39]. In broad terms, as the 
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glycosylation at N130 is close to the β-sheet and turret loop it seems plausible that initial effects may 
occur on these elements and may then be progressively transmitted back down the rest of the receptor, 
appearing as regions of reduced or enhanced flexibility as observed.  
Interestingly, the binding of either RAMP1 or RAMP2 to CTR did not appear to alter the glycan 
effect in the amylin receptors.  Based on similarity to the CGRP receptor, the RAMPs very likely bind to 
the CTR α-helix. Presumably these contacts do not substantially alter the dynamics of the CTR ECD that 
are relevant to the glycan effect, although we have previously suggested that a major component of 
RAMP1 action is to alter the dynamics of the CTR, specifically the loop between β3 and β4, the loop 
distal to β4 and the turret loop and C-terminus [16]. It is intriguing that in the current study, we again find 
evidence for changed mobility in all of these areas except for the extreme C-terminus. 
Overall effects of N-glycosylation on receptor function  
The functions of protein N-glycosylation have been studied for several decades. Protein folding and 
consequential quality control of producing functional protein are often critical roles of N-glycans [28]. 
Glycans can modulate molecular interactions especially with the proteins expressing lectin domains or 
through steric effects on protein conformation and binding [29]. McElroy et al., reported a dramatic 
example of intermolecular binding promotion mediated by N-glycosylation of a cell surface receptor that 
bears similarities to our results presented here [40]. They showed that N-glycosylation of the IL-7 
receptor α unit (IL-7Rα) ectodomain significantly increased IL-7 binding affinity. From the kinetics assay, 
this large affinity increase was primarily derived from an accelerated association rate of IL-7. They 
obtained crystal structures of glycosylated and non-glycosylated IL7/IL-7Rα complex and found that N-
glycosylation of IL-7Rα did not induce large conformational changes and that IL-7 did not contact the 
receptor N-glycans. They speculated that the N-glycans altered the receptor conformational dynamics, but 
did not present evidence for this.  N-glycan-mediated alteration of receptor dynamics may be a more 
widespread mechanism affecting ligand-receptor interactions than has been appreciated. 
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Studies with structural comparison were reported using available crystal structures of glycosylated 
proteins and their corresponding non-glycosylated versions [41, 42]. These reports found that N-
glycosylation generally does not induce dramatic conformational changes of protein structure, consistent 
with our findings for CTR. Lee et al. further performed MD simulations and reported that N-glycosylation 
decreased the dynamic fluctuations of the proteins tested, which probably increased their stabilities. 
Interestingly, in the case of our CTR results shown here we not only observed an N-glycan-mediated 
stabilizing effect, but also an increased flexibility of the turret loop in the peptide-binding site. Our results 
thus suggest that N-glycans may in some cases also increase protein dynamics to enhance ligand-receptor 
interactions.   
N-glycosylation effects on other class B GPCRs  
The class B GPCR ECD fold is highly conserved. Notably, six of the fifteen human class B GPCRs 
have an N-glycosylation site equivalent to CTR N130 raising the possibility that ligand interactions with 
other class B GPCRs may be also be affected by N-glycosylation. Early reports on N-glycosylation 
effects on the related CLR yielded conflicting results with evidence both for and against a role of N-
glycosylation in ligand binding at CLR [43, 44]. Here, we showed that the glycan effect is conserved in 
the heterodimeric CGRP receptor (RAMP1-CLR) and that the N123 site was responsible for the effect.  
Given the modeling of GlcNAcs on the CGRP receptor presented in Figure S10 it seems likely that the 
CLR N123 GlcNAc does not contact the bound peptide ligand and probably does not significantly alter 
the binding mode. Thus, we propose that the CLR N123 N-glycan alters CLR dynamics similar to what 
we observed here for CTR. 
Interestingly, although the PTH1R receptor has N-glycan sites equivalent to CTR N130 and N125 in 
the turret loop there is clear evidence that PTH1R N-glycosylation has no effect on receptor function. 
Tunicamycin treatment with the human PTH type 1 receptor (PTH1R) expressed in mammalian cells 
showed no changes in PTH binding affinity and PTH potency for the receptor activation [45]. The recent 
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crystal structure of the human full-length PTH1R with bound PTH showed that a fucose attached to the 
proximal GlcNAc residue of PTH1R N161 in the turret loop locates in proximity to the main chain of 
PTH Y34 and forms a polar interaction [46]. However, the N161D mutation of PTH1R did not change the 
binding affinity for PTH indicating that the glycan interaction with PTH Y34 observed in the crystal 
structure is dispensable for PTH binding to its receptor. Figure S10E shows structural comparison with 
PTH1R ECD-PTH and CTR ECD-sCT. The proximal GlcNAc residue of PTH1R N166 positions 
similarly to that of CTR N130. However, the ECD binding C-terminal part of PTH was much closer to 
the α1 region of PTH1R than corresponding sCT. In addition, the turret loop of PTH1R ECD is more 
distant from PTH than the distance of the turret loop of CTR ECD from sCT. These structural differences 
may contribute to the differences in N-glycosylation effects at these two receptors. Compared to a 
relatively stable PTH helical domain, the flexible conformation of sCT may also be involved in the 
affinity-enhancing effect of receptor N-glycosylation. 
Other class B GPCRs have also been reported to elicit N-glycosylation effects on their functions. 
Chen et al., showed that the glucagon-like peptide 1 receptor (GLP-1R) significantly reduced GLP-1 
affinity and signaling potency by the double mutations of two N-glycosylation sites [47]. Pituitary 
adenylate cyclase activating polypeptide (PACAP) type I (PAC1) receptor showed a significant 30-fold 
decrease in PACAP-27 affinity by tunicamycin treatment without altering binding capacity [48]. In 
addition, mutagenesis of N-glycosylation sites was reported to diminish the expression level of the 
glucose-dependent insulinotropic polypeptide (GIP) receptor [49], the vasoactive intestinal peptide (VIP) 
1 receptor [50], the glucagon receptor (GCGR) [51], and the secretin receptor [52]. The corticotropin 
releasing factor receptor type 1 (CRF1R) with a single N-glycosylation site mutation expressed the 
receptor comparable to WT. However, the combined mutations of three sites decreased the receptor 
expression and consequentially reduced ligand binding and CRF potency for receptor activation [53]. 
Interestingly, the corresponding N130 residue of CTR ECD is conserved as N98 of CRF1R and CRF2R. 
How N-glycans of CRF1R N98 contribute to CRF binding affinity still remains to be clearly addressed in 
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a future study.  
Closing remarks 
Class B GPCRs are physiologically important receptors and drug targets of multiple drugs. Evidence 
provided by this study suggests that N-glycosylation of CTR extracellular domain modulates receptor 
dynamics rather than global conformation. Amylin and CGRP receptors also enhance ligand affinity by 
receptor N-glycosylation. Most of other class B GPCRs and various cell surface receptors have shown 
that N-glycans at least to some degree contribute to their cell surface expression and/or functions. 
Although there are exceptions against the currently known functions of protein N-glycans, structural 
mechanism provided by this study suggests that dynamic allostery, an important concept little applied to 
GPCRs, may be significant for understanding their mechanisms. This information will inform the GPCR 
field and can be considered for peptide drug development towards improved binding profile. 
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MATERIALS AND METHODS 
Reagents 
DMEM with 4.5 g/L glucose and L-glutamine, and non-essential amino acid mixture were purchased 
from Lonza (Basel, Switzerland). FBS was from Life Technologies (Carlsbad, CA). HEK293S GnTI- and 
HEK293T cells were purchased from ATCC (Manassas, VA) and ThermoScientific (Waltham, MA), 
respectively. PNGase F was purchased from New England Biolabs (NEB, Ipswich, MA). Gibson 
Assembly Master Mix and required restriction enzymes were purchased from NEB. Crystal screening 
blocks were purchased from Hampton Research (Aliso Viejo, CA). All other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO), unless otherwise noted.  
Cell lines  
HEK293S GnTI- cells were used to express glycosylated MBP-CTR ECD with Man5GlcNAc2 N-
glycans, which are sensitive to Endo H-mediated N-glycan trimming. CTR ECD WT and N130D mutant 
and RAMP1-CTR ECD fusion WT and N130D mutant were also expressed from HEK293S GnTI- cells. 
HEK293T cells were used to express fully glycosylated MBP-CTR ECD, RAMP1-CLR ECD fusion, and 
their mutants. HEK293T cells were cultured at 37C, 5% CO2 in Dulbecco’s Modified Eagle Media 
(DMEM) plus 10% fetal bovine serum (FBS). HEK293S GnTI- cells were cultured at the same condition 
and media as those used for HEK293T cells except supplementing non-essential amino acid mixture to 
the culture media. Both cell lines were directly purchased from the suppliers and have not been 
authenticated. Information on sex of the cell lines is not available.   
Bacterial cells 
Origami B DE3 cells from Novagen containing the trxB gor mutations were used for expression and 
purification of MBP-TEV cleavage site-CTR ECD from E. coli.  
Plasmids 
pHLsec-based vectors were used for N-glycosylated protein expression from mammalian cells as 
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secreted proteins [54]. The Gibson Assembly method was used for constructing plasmids and 
mutagenesis of receptor ECDs. pHLsec/MBP-hCTR.38-141-H6 (pSL015) and pHLsec/MBP-hCTR.40-
141-H6 (pSL017) were generated for crystal screening of MBP-CTR ECD. pHLsec/MBP-hCTR.38-141-
H6 W128H (pSL018), F119L (pSL019), F119H (pSL020), M133A (pSL021), and T109V (pSL022) were 
produced for a mutagenesis study. MBP in above plasmids contain a linker sequence NAAAEF at the C-
terminal end of MBP sequence. Plasmids of pHLsec/MBP-TEV cleavage site-hCTR.34-141-H6 (pSL052), 
pHLsec/MBP-TEV cleavage site-hCTR.38-141-H6 WT (pSL031) and N130D (pSL033), pHLsec/MBP-
TEV cleavage site-hRAMP1.24-111-(GSA)3-hCTR.34-141-H6 WT (pSL041) and N130D (pSL048), 
pHLsec/MBP-TEV cleavage site-hRAMP2.55-140-(GSA)3-hCTR.38-141-H6 (pSL042), and 
pHLsec/MBP-TEV cleavage site-hRAMP1.24-111-(GS)5-hCLR.29-144-H6 WT (pSL039) and N123D 
(pSL047) were generated to produce MBP-free receptor ECDs. A pETDuet-1 vector was used for the 
expression of MBP-TEV cleavage site-CTR.38-141-H6 from E.coli as a glycan-free from (pSL035). The 
TEV cleavage site represented in above plasmids encodes GSSSGGGENLYFQGS including a linker 
prior to a TEV cleavage site. Coding sequences of all plasmids were confirmed by automated DNA 
sequencing performed by the University of Oklahoma Health Sciences Center Laboratory for Molecular 
Biology and Cytometry Research core facility. These plasmids were purified for transient transfection 
using a Macherey-Nagel Midi or Giga kit according to the manufacturer’s directions.  
Glycosylated receptor ECD expression and purification 
General procedures of glycosylated receptor MBP-ECD expression and purification were previously 
described [12, 18]. All purifications were performed at 4°C unless otherwise noted. To produce MBP-
CTR ECD bearing proximal GlcNAcs for crystallization, glycosylated MBP-CTR ECD was expressed 
from HEK293S GnTI- cells in six roller bottles (MIDSCI, Cat# HRBV-1900, 1900 cm2/bottle, rolling 
speed 0.2 RPM) at 37°C for 4 days after plasmid transfection with polyethyleneimine (PEI). The 
expressed MBP-CTR ECD was purified with immobilized Ni metal affinity chromatography (IMAC). 
The peak fractions were pooled and incubated with 1:10 ratio (w/w, Endo H: protein), while dialyzing to 
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25 mM MOPS (pH 6.5) and 150 mM NaCl at 4°C overnight. Next day, pH of the mixture was adjusted to 
pH 7.5 with 1 M Tris HCl (pH 9.0) and purified with IMAC. The peak fractions were pooled and 
concentrated using a spin concentrator with 10kDa MWCO (Millipore). The concentrated solution was 
purified with size-exclusion chromatography (SEC). The Endo H-treated MBP-CTR ECD purified as a 
monomer and was used for crystal screening. Fully glycosylated MBP-CTR ECD WT and mutants were 
expressed from HEK293T cells in six T175 flasks for 3 days at 37°C after PEI transfection and purified 
with IMAC and following SEC. The monomer peak fractions were pooled, dialyzed to storage buffer (25 
mM HEPES pH 7.5, 150 mM NaCl, and 50% (v/v) glycerol) overnight, and stored at -80°C until use. 
For BLI and HDX-MS experiments, Endo H-treated, MBP-free CTR ECD WT and N130D were 
produced as below. MBP-TEV cleavage site-CTR ECD WT and N130D were first expressed from 
HEK293S GnTI- cells in six roller bottles as described above. Expressed proteins were purified by IMAC 
and the peak fractions were pooled and incubated with 1:5 ratio (w/w, TEV protease: protein) at 20°C for 
6 h. Then, the reaction mixture was incubated with 1:10 ratio (w/w, Endo H: protein), while dialyzing to 
25 mM MOPS (pH 6.5) and 150 mM NaCl at 4°C overnight. Next day, pH of the equilibrated mixture 
was adjusted to pH 7.5 with 1M Tris HCl (pH 9.0) and the pH-adjusted mixture was further purified with 
IMAC and following SEC. The peak fractions were pooled, dialyzed to storage buffer described above, 
and stored at -80°C until use.  
To produce MBP-free RAMP1-CTR ECD and RAMP1-CLR ECD fusions, MBP-TEV cleavage site-
receptor ECD was expressed from HEK293S GnTI- or HEK293T cells. The expressed MBP-TEV 
cleavage site-receptor ECD was initially purified by IMAC. Then, the peak fractions were pooled and 
incubated with 1:5 ratio (w/w, TEV protease: protein) at 20°C overnight. After TEV protease reaction, the 
mixture was purified with IMAC and following SEC. The peak fractions were pooled, dialyzed to storage 
buffer described above, and stored at -80°C until use. Receptor ECD concentrations were measured by 
either UV absorbance at 280 nm using extinction coefficients calculated from Tyr, Trp and Cystine 
residues or Bradford assay with a BSA standard curve.  
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Glycan-free receptor ECD expression in bacteria and purification 
General procedures of glycan-free MBP-CTR ECD expression and its purification were previously 
described [18]. MBP-TEV cleavage site-CTR ECD expressed from E. coli Origami B (DE3) was purified 
with IMAC. The peak fractions were pooled and subjected to disulfide shuffling reaction in the presence 
of RAMP2 ECD at 20°C overnight for proper folding. Next day, the reaction mixture was purified with 
amylose affinity chromatography and following SEC. The purified sample was incubated with 1:5 ratio 
(w/w, TEV protease: protein) at 20°C for 6 h. Then, the reaction mixture was dialyzed to 50 mM Tris HCl 
(pH 7.5), 150 mM NaCl, 10% (v/v) glycerol at 4°C overnight to remove bound maltose. Next day, the 
equilibrated mixture was applied to amylose affinity chromatography. The peak fractions were pooled and 
further purified with IMAC. The final peak fractions were dialyzed to storage buffer described above and 
stored at -80°C until use.      
Synthetic peptides 
All peptides used in this study were custom-synthesized and HPLC-purified by RS Synthesis 
(Louisville, KY). The lyophilized powders were dissolved in sterile ultrapure water at an approximate 
peptide concentration of 10 mg/mL and multiple aliquots were stored at -80°C until use. The peptide 
stock concentration was determined by UV absorbance at 280 nm using extinction coefficients calculated 
from Tyr, Trp and Cystine residues after the peptide was 50-fold diluted with 10 mM Tris and 1 mM 
EDTA (pH 8.0). A FITC extinction coefficient (72,000 M-1 cm-1 at 495 nm, pH 8.0) was used to measure 
the concentration of FITC-labeled peptides. 
Crystallization, diffraction data collection, structure solution, and refinement 
Endo H-treated MBP-CTR.38-141-H6 and MBP-CTR.40-141-H6 were incubated with sCT(16-32) 
and sCT(22-32), respectively at 1:1.3 molar ratio (protein: peptide) for 1 h on ice. The protein-peptide 
mixture was concentrated to 30 mg/mL as previously described [24]. Crystals of MBP-CTR.38-141-H6 
with sCT(16-32) were grown by hanging drop vapor diffusion in 34% (v/v) pentaerythritol ethoxylate 
(15/4 EO/OH), 0.05M Bis-Tris (pH 6.8), and 0.1 M ammonium sulfate. In addition, crystals of MBP-
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CTR.40-141-H6 with sCT(22-32) was grown by hanging drop vapor diffusion in 1.94 M ammonium 
sulfate and 0.1 M sodium acetate (pH 4.7). The MBP-CTR.38-141-H6 crystals were flash frozen in liquid 
nitrogen without any additional cryoprotectant, whereas the MBP-CTR.40-141-H6 crystals were dialyzed 
overnight to the reservoir solution supplemented with 15% (v/v) ethylene glycol for cryoprotection and 
flash frozen in liquid nitrogen. Diffraction data were collected remotely at the LS-CAT beamlines 21-ID-
F and -G of the Advanced Photon Source (Argonne, IL). A set of diffraction images from a single crystal 
was processed with HKL2000 [55] and the CCP4 suite [56]. Phaser was used for molecular replacement 
(MR) with MBP and CTR ECD (PDB 5II0, chain A) as search models (both ligand-free). The MR model 
was rebuilt and ligands and GlcNAcs were added with COOT [57]. REFMAC5 [58] was used for TLS 
and restrained refinement. Automatic NCS restrains were applied for the sCT(16-32)-bound MBP-
CTR.38-141-H6 structural model with two molecules in the asymmetric unit.  
For modeling GlcNAcs with energetically favorable 4C1 conformation, the torsion angles of GlcNAc 
(three letter code for REFMAC library: NAG) were restrained. The process of GlcNAc model building 
with the 4C1 conformation was previously described [59]. A normal NAG library file was generated with 
ACEDRG software in the CCP4 suite [60], which produced the lowest energy NAG conformer. Torsion 
angles of the lowest energy conformer were measured using Pymol. The generic torsion angles of the 
NAG library file were replaced with the measured torsion angles of the lowest energy NAG conformer. 
The torsion angle-restrained NAG was added to asparagine of CTR ECD using a carbohydrate module in 
COOT. The normal NAG-ASN linker file was also generated using JLigand [61] and was combined with 
the torsion angle-restrained NAG library file to produce a single library file for REFMAC5 refinement. 
After final refinement with REFMAC5, Privateer software in the CCP4 suite was used to validate the 
geometry and conformation of GlcNAcs [62]. All GlcNAcs added in the CTR ECD structural models 
retained the 4C1 conformation without any stereochemical problems.    
Fluorescence polarization/anisotropy (FP) peptide binding assay 
Equilibrium peptide binding assay with saturation and competition binding formats was performed 
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as previously described at room temperature [18]. FITC-labeled sCT(22-32), AC413(6-25) WT, 
AC413(6-25) [Y25P], and AM(37-52) [S45W/Q50W] were used as probes. The reaction buffer consists 
of 50 mM HEPES (pH 7.4), 150 mM NaCl, 0.5 mg/mL fatty acid-free BSA, 0.5 mM maltose, 0.5 mM 
EDTA, and 0.1% (v/v) Tween 20. A probe concentration 10 nM was used in all experiments except 7 nM 
was used for FITC-AM(37-52) [S45W/Q50W]. For the competition-binding assay, a receptor 
concentration that is two times the KD value was used (KD 501 nM, KD 1995 nM, and KD 2691 nM for 
Endo H-treated CTR ECD WT, N130D, and E. coli-produced CTR ECD, respectively). A PolarStar 
Omega plate reader (BMG Labtech) was used to read fluorescence polarization/anisotropy. Data analysis 
and nonlinear regression curve fitting were performed with PRISM 7.0 as previously described [18].  
PNGase F-catalyzed deglycosylation 
Glycosylated receptor ECDs produced from HEK293S GnTI- or HEK293T cells were treated with 
PNGase F to remove all N-glycans as previously described [18]. 
BLI kinetic assay 
Endo H-treated CTR ECD WT and N130D and E. coli-produced glycan-free CTR ECD WT were 
used for BLI kinetic assay. An Octet-RED96 system with streptavidin-coated sensors (ForteBIO, SAX 
biosensors) was used to measure binding kinetics with an immobilized, biotinylated sCT(1-32) 
[C1A/C7A] peptide. The assay buffer was 50 mM HEPES (pH 7.4), 150 mM NaCl, 5 mg/mL fatty acid-
free BSA, 0.5 mM maltose, 0.5 mM EDTA, and 0.1% (v/v) Tween 20. All steps were conducted at 25°C 
with each biosensor stirred at 1000 RPM in 0.2 mL of samples. The biosensors were pre-equilibrated with 
the assay buffer for at least 30 min before use. The sensors were first equilibrated with the assay buffer 
for 120 sec. Then, the sensors were loaded with 25 nM biotinylated sCT for 200 sec, which occupies ~ 25% 
of total binding capacity of each sensor. After 60 sec washing and additional 120 sec equilibrium steps 
with the assay buffer, the sensors were dipped into CTR ECD samples to measure an association rate for 
50 sec. Then, the sensors were transferred to the wells with assay buffer alone for 100 sec to start the 
dissociation phase. The standard kinetics (5.0Hz, averaging by 20) was used as an acquisition rate. 
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ForteBio data analysis software (version 8.1) was used to obtain kinetic parameters. Five different 
concentrations of CTR ECD were used for the kinetic assay. Endo H-treated and glycan-free CTR ECDs 
in the assay buffer did not show non-specific binding to the sensor. Endo H-treated CTR ECD N130D 
showed non-specific binding for the sensor to some degrees particularly at 4 µM concentration. The non-
specific binding of high concentration CTR ECD N130D to an empty sensor was subtracted from the total 
binding signal of the samples. The reference well with the assay buffer alone was used as baseline for 
other samples for data processing. After reference well subtraction, Y axis was aligned according to BLI 
signal during the last 5 sec of the equilibrium step prior to the association. Inter-step correction was 
performed by aligning to the dissociation phase and Savitzky-Golay filtering option was applied. Both 
association and dissociation phases from the process data were used for curve fitting by applying a 1:1 
binding model and a global fitting option. Processed BLI signals and their curve fitting results (until 50 
sec of the dissociation phase) were exported from ForteBio data analysis software and PRISM 7.0 was 
used for figure representation.    
HDX-MS analysis  
Following protein samples are prepared in 100 µM: Endo H-treated CTR ECD WT and N130D 
either with or without 100 µM sCT. Hydrogen/deuterium exchange was initiated by mixing 4 µL of each 
protein samples with 26 µL of D2O buffer (25 mM HEPES, pD 7.4, 150 mM NaCl, 10% glycerol) and 
incubating for 10, 100, 1000, or 10000 sec on ice. For the sCT-bound samples, 15 µM salmon calcitonin 
was additionally added in the D2O buffer. At the indicated time points, each mixture was quenched by 
adding 30 µL of ice-cold quenching buffer (0.1 M NaH2PO4, pH 2.01, 20 mM TCEP, 1 M guanidine 
hydrochloride). For non-deuterated samples, 4 µL of protein samples are mixed with 26 µL of H2O buffer 
(25 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol) and quenched by 30 µL of ice-cold quench buffer. 
Back-exchange level was not corrected because all the data is comparison of different states and the fully 
deuterated samples were aggregated. The quenched samples were digested by passing through an 
immobilized pepsin column (2.1 x 30 mm) (Life Technologies, Carlbad, CA, USA) at a flow rate of 100 
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µL/min with 0.05% formic acid in H2O at 12°C. The digested fragments were collected on a C18 
VanGuard trap column (Waters, Milford, MA, USA) and desalted with 0.15% formic acid in H2O. The 
fragments were subsequently separated by ultra-pressure liquid chromatography using an ACQUITY 
UPLC C18 column (1.7 µm, 1.0 mm x 100 mm) (Waters, Milford, MA, USA) at a flow rate of 40 µL/min 
with an acetonitrile gradient starting with 8% and increasing to 85% over 7.5 min. To minimize the back 
exchange of deuterium to hydrogen, the system including trapping and UPLC column was maintained at 
0.5°C during the analysis and all buffers were adjusted to pH 2.5. Peptic peptides were identified from the 
non-deuterated samples with ProteinLynx Global Server (PLGS) 3.0 (Waters, Milford, MA, USA). The 
following parameters were applied: monoisotopic mass, nonspecific enzyme digestion allowing up to one 
missed cleavage, automatic fragment mass tolerance and automatic peptide mass tolerance. Searches were 
performed with the variable methionine oxidation modification. The amount of deuterium of peptic 
peptides at each time point was determined by measuring the centroid of the isotopic distribution using 
DynamX 3.0 (Waters, Milford, MA, USA). 
MD simulations 
Replica Exchange Monte Carlo (REMC) simulations were performed using Gromacs software [63] 
with sixteen temperatures ranging between 300-500K; 1 node a temperature point were used in all 
simulations. Three chains (Mol A, B, and C) of glycan-free CTR ECD structure (PDB 5II0), two chains 
(Mol A and B) of 1.78Å CTR ECD structure, and their non-glycosylated versions without GlcNAc 
residues were used. Residues 44 to 136 of the 1.78Å CTR ECD structure were selected for MD 
simulations to make a complete comparison to glycan-free CTR ECD (PDB 5II0). Alternative backbone 
A of 1.78Å CTR ECD Mol B structure was chosen since it is more consistent with the corresponding 
region of CTR ECD Mol A. The REMC simulations used 16 temperatures ranging between 300 to 500K 
and lasted for 500 ns. The resulting trajectory of three chains of glycan-free CTR ECD and two chains of 
either glycosylated or non-glycosylated CTR ECD were combined and first eigenvector was used to 
calculate RMSF. VMD was used to visualize CTR ECD flexibility during the MD simulations [64].   
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Molecular modeling and structure figures 
Pymol (Schrodinger) was used for the representation of the structural figures. The structural models 
of MBP-CTR ECD W128H, F119H, F119L, M133A, and T109V mutants were generated by the 
mutagenesis wizard in Pymol. Glycosylated and glycan-free CTR ECDs were superimposed by aligning 
CTR ECDs with Pymol. For the glycosylated CGRP receptor ECD structure, the cryo EM structure of the 
full-length CGRP receptor was used (PDB 6E3Y) and the proximal GlcNAc residues of its ECD were 
modeled with COOT based on the cryo EM density map of N-glycans. The homology model of the 
amylin receptor ECD was generated based on the full-length CGRP receptor structure (PDB 6E3Y) by 
replacing CLR ECD with the 2.85Å CTR ECD structure after alignment. PTH1R ECD (PDB 6FJ3) was 
aligned with the 2.85Å CTR ECD structure using Pymol.    
Sequence alignment of class B GPCR ECDs 
ClustalX2 was used with identity matrix for sequence alignment [65]. The alignment was adjusted 
minimally for conserved residues. The following human class B GPCR ECDs were used: calcitonin 
receptor (CALCR, CBN80566.1), calcitonin-like receptor (CLR, AAA62158.1), parathyroid hormone 
receptor 1 (PTH1R, AAR18076.1), parathyroid hormone receptor 2 (PTH2R, EAW70451.1), 
corticotropin-releasing factor receptor 1 (CRFR1, AAC69993.1), corticotropin-releasing factor receptor 2 
isoform 2 precursor (CRFR2b, NP_001189404.1), glucagon-like peptide-1 receptor (GLP1R, 
AAA17021.1), glucagon-like peptide 2 receptor (GLP2R, NP_004237.1), glucagon receptor (GCGR, 
AAC52063.1), secretin receptor (SCTR, AAA64949.1), growth hormone-releasing hormone receptor  
(GRHR, AAA35890.1), GIP receptor (GIPR, AAA84418.1), pituitary adenylate cyclase activating 
polypeptide 1 receptor (PAC1, EAW93978.1), vasoactive intestinal peptide receptor 1 (VIPR1, 
AAH64424.1), and vasoactive intestinal peptide receptor 2 (VIPR2, EAX04596.1). ESPript 3.0 was used 
for figure representation [66].  
Statistical analysis 
Three or more independent experiments (on different days) were performed both for FP equilibrium 
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binding assay and BLI kinetic assay, unless otherwise noted. Duplicate samples of each receptor 
concentration were used for the individual FP equilibrium binding experiment, while BLI kinetics assay 
used a single sample of each receptor concentration. pKD and pKI from FP binding assay and kon, koff, and 
calculated pKD from BLI kinetic assay were reported as Mean ± SEM. PRISM 7.0 was used for one-way 
analysis of variance (ANOVA) followed by Tukey’s post-hoc test for multiple comparisons. For HDX-
MS, a Student’s t-test was used. p < 0.05 was regarded as statistical significance. The details of statistical 
analysis used for the representative figures can be found in the figure legends.    
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FIGURE LEGENDS 
Figure 1. Crystal structures of sCT bound to proximal GlcNAc-bearing CTR ECD 
(A) The 1.78Å CTR ECD structure. (B) The 2.85Å CTR ECD structure. See Figure S1 for MBP-fused 
CTR ECD in the asymmetric unit cell. MBP is omitted for clarity. See Figure S2 for the electron density 
of N130 GlcNAc. (C and D) The detailed view of sCT interaction with CTR ECD. Hydrogen bonds are 
represented as a gray dotted line. See also Figure S4.   
 
Figure 2. Comparisons of the GlcNAc-bearing structures to the N-glycan free CTR ECD structure  
(A) 1.78Å and (B) 2.85Å sCT-CTR ECD complexes were aligned with Mol A of the sCT-bound glycan-
free CTR ECD from PDB ID 5II0. Mol B and Mol C of sCT-bound glycan-free CTR ECD were also 
aligned with sCT-bound glycan-free CTR ECD Mol A. See also Figure S4.  
 
Figure 3. Equilibrium and kinetic analyses of sCT binding to CTR ECD glycoforms 
(A) Equilibrium saturation binding FP assay assessing binding of the indicated CTR ECD glycoforms to a 
FITC-sCT(22-32) probe. (B) Equilibrium FP competition binding assay assessing displacement of the 
probe by unlabeled sCT(22-32). FP assay was performed with duplicate samples at each receptor 
concentration using FITC-sCT(22-32) as a probe. Data points in the plot were shown as mean with SEM 
as error bars. When the error bars were shorter than the height of the symbol, the error bars were omitted. 
(C-E) sCT binding kinetics was measured with biolayer interferometry assay. Mean values of KD, kon, and 
koff were shown. Representative curves of both FP and kinetic assays were shown from at least three 
independent experiments.     
 
Figure 4. N-glycosylation of CTR N130 alters ECD conformational dynamics 
Selected CTR ECD residues corresponding to the peptide fragments were color-coded on the 2.85Å CTR 
ECD structure, and the deuterium uptake plots were provided. See Figure S6 for HDX results in the 
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presence of excess sCT. See also Figure S7. HDX results were shown as mean ± SEM from at least three 
independent experiments. The statistically significant differences were analyzed by a Student’s t-test (* p 
< 0.05). 
 
Figure 5. Molecular dynamics (MD) simulations with CTR ECD with or without GlcNAcs 
(A) RMSF (Root Mean Squared Fluctuation) for the dynamics of the GlcNAc-bearing 1.78Å CTR ECD 
and glycan-free CTR ECD (PDB 5II0). Residues 44-136 were used for all MD simulations. Averaged 
RMSF values were shown from two molecules of the 1.78Å structure and three molecules of glycan-free 
CTR ECD present in the asymmetric unit. (B) RMSF for the dynamics of the GlcNAc-removed 1.78Å 
CTR ECD and glycan-free CTR ECD (PDB 5II0). (C-F) RMSF of CTR ECD was visualized using VMD 
showing five representative frames during the MD simulations. Two end frames of each direction were 
colored with blue or red, and the middle frame was colored with gray.    
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TABLES  
Table 1. X-ray diffraction data collection and refinement statistics.  
Data collection   
Space group P6522 P4132 
Cell dimensions   
    a, b, c (Å) 121.03, 121.03, 263.96 181.29, 181.29, 
181.29 
    α, β, γ (°)  90, 90, 120 90, 90, 90 
Resolution (Å) 50.0 – 1.78 50.0 – 2.85 
Rmerge  0.066 (0.954) a 0.122 (1.440) a 
CC1/2 (0.628) a (0.614) a 
I / σI 29.82 (1.38) a  21.24 (1.32) a 
Completeness (%) 99.0 (97.0) a 99.0 (99.7) a 
Redundancy 7.4 (5.9) a 9.3 (9.3) a 
 
  
Refinement   
Resolution (Å) 49.86 – 1.78 48.45 – 2.85 
No. reflections 103153 22878 
Rwork / Rfree 0.186/0.214 0.193/0.225 
Protein molecules/ASU 
No. atoms 
    Protein(+GlcNAc) /peptide 
    Heterogen atoms (Maltose, etc.) 
    Water 
2 
8740 
8037 
51 
652 
1 
3874 
3845 
27 
2 
No. of TLS groups 6 3 
B-factors (Mol A/B or Mol A)   
    MBP 27.4/33.3 84.6 
    CTR ECD (+GlcNAc) 48.3/34.3 73.3 
    sCT 36.2/39.7 97.8 
    Water 35.0 68.2 
RMS deviations   
    Bond lengths (Å) 0.015 0.015 
    Bond angles (°) 1.68 1.83 
Ramachandran Analysisb   
    Preferred regions (%) 97.1 97.3 
    Allowed regions (%) 2.9 2.7 
    Outliers (%) 0 0 
All-atom Clashscorec 2.44 (99th percentile) 3.28 (100th percentile) 
MolProbity scorec 1.35 (97th percentile) 1.78 (100th percentile) 
aValues in parentheses are for highest-resolution shell. 
bAs defined by COOT. 
cAs determined by MolProbity. Values in parentheses represent rank among structures of similar 
resolution. 
  
Table 2. Peptide ligand affinity measured by FP assay 
Receptor ECD Expression Enzyme 
treatment 
N Mean ± SEM 
Figure 3A    pKD of FITC-sCT(22-32) 
CTR.38-141 WT HEK293S GnTI- Endo H  5 6.30 ± 0.03 (0.50 ± 0.03)b 
CTR.38-141 N130D HEK293S GnTI- Endo H  3 5.70 ± 0.03a (2.0 ± 0.13) 
Glycan-free CTR.38-141 WT E. coli None 4 5.57 ± 0.03a (2.7 ± 0.20) 
     
Figure 3B    pKI of sCT(22-32) 
CTR.38-141 WT HEK293S GnTI- Endo H 4 5.81 ± 0.03 (1.6 ± 0.12) 
CTR.38-141 N130D HEK293S GnTI- Endo H 3 5.26 ± 0.04a (5.6 ± 0.48) 
Glycan-free CTR.38-141 WT E. coli None 4 4.97 ± 0.07a (11 ± 1.7) 
     
Figure S8A    pKD of FITC-AC413(6-25) 
RAMP1-CTR.34-141 WT HEK293S GnTI- None  3 5.89 ± 0.08 (1.3 ± 0.21) 
CTR.34-141 WT HEK293S GnTI- None 3 4.67 ± 0.12 (23 ± 5.8) 
     
Figure S8B    pKD of FITC-sCT(22-32) 
RAMP1-CTR.34-141 WT HEK293S GnTI- None 3 6.56 ± 0.06 (0.28 ± 0.04) 
CTR.34-141 WT HEK293S GnTI- None 3 6.43 ± 0.06 (0.38 ± 0.06) 
     
Figure S8D    pKD of FITC-AC413(6-25) 
RAMP1-CTR.34-141 WT HEK293S GnTI- None 3 6.04 ± 0.03 (0.92 ± 0.07) 
RAMP1-CTR.34-141 WT HEK293S GnTI- Inactive PNGase F 3 6.01 ± 0.03 (0.97 ± 0.06) 
RAMP1-CTR.34-141 WT HEK293S GnTI- PNGase F 3 < 5.0 (> 10) 
RAMP1-CTR.34-141 N130D HEK293S GnTI- None 3 5.12 ± 0.07a (7.9 ± 1.4) 
     
Figure S10C    pKD of FITC-AM analog 
RAMP1-CLR.29-144 WT HEK293T None 3 6.51 ± 0.02 (0.31 ± 0.01) 
RAMP1-CLR.29-144 WT HEK293T Inactive PNGase F 3 6.56 ± 0.07 (0.28 ± 0.05) 
RAMP1-CLR.29-144 WT HEK293T PNGase F 3 5.87 ± 0.04a (1.4 ± 0.13) 
RAMP1-CLR.29-144 N123D HEK293T None 3 6.13 ± 0.01a (0.74 ± 0.01) 
a
 p < 0.05 compared to the glycosylated receptor ECD WT with Endo H treatment (Figure 3A and 3B) or 
none treatment (Figure S8D and S10C). ANOVA with Tukey’s post hoc test was used for statistical 
analysis. b KD or KI values in µM are given in parenthesis. 
  
Table 3. sCT binding kinetic parameters from biolayer interferometry 
CTR.38-141  Mean ± SEM 
 N kon (1 x 104/Ms) koff  (1/s) Calculated KD (µM) Steady state KD (µM) 
Endo H-treated 
WT 3 17.8 ± 2.0 0.37 ± 0.02 2.1 ± 0.1 1.9 ± 0.2 
Endo H-treated 
N130D 3 6.3 ± 1.0
a
 0.73 ± 0.03a 12.4 ± 2.5a 11.9 ± 1.7a 
Glycan-free 
WT 3 2.1 ± 0.5
a
 0.61 ± 0.03a 30.9 ± 5.3a 10.8 ± 2.2a 
All kinetic parameters were produced from ForteBio data analysis software (version 8.1). 
a
 p < 0.05 compared to Endo H-treated CTR.38-141 WT. ANOVA with Tukey’s post hoc test was used 
for statistical analysis.  
 





HIGHLIGHTS (85 CHARACTERS PER BULLET POINT) 
• How N-glycosylation enhances ligand affinity of the calcitonin receptor is unknown. 
• Crystal structures of calcitonin bound to N-glycosylated calcitonin receptor ECD. 
• MD simulations and HDX-MS experiments show that N-glycans modulate ECD dynamics. 
• N-glycans similarly enhance ligand affinity of related amylin and CGRP receptors. 
• N-glycosylation of GPCRs can modulate their function by altering receptor dynamics. 
